Delivery Order SPE2DB24D3015-SPE2DB25FGABL
- Not listed
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded a delivery order valued at $1,444.50 to AmerisourceBergen Drug Corp on July 23, 2025, with an ultimate completion date of July 24, 2025. This contract represents a child delivery order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award employs firm fixed pricing with no set-aside designation,...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency Medical Supply Chain awarded a $5,444.80 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The delivery order will be performed at the vendor's corporate office location in...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order valued at $17,524.44 to AmerisourceBergen Drug Corp on July 27, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $1,250.47 to AmerisourceBergen Drug Corp on August 16, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $4,216.30 to AmerisourceBergen Drug Corp on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award represents a pharmaceutical delivery to be...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for ORSERDU 345 mg tablets in a 30-count package. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $27,841.82 with an ultimate completion date of August 11, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded a delivery order valued at $81,150.96 to AmerisourceBergen Drug Corp on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The order will be performed at the company's corporate office...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $1,004.85 to AmerisourceBergen Drug Corp on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award to the prime contractor under its broader contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,755.66 firm fixed-price contract is for the supply of 4,567,341,454 units of Nystatin 100,000 unit/mL suspension in 60 mL bottles. The contract has an ultimate completion date of February 24, 2025 and was awarded on February 21, 2025. This contract award is associated with...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGABLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,125.92 to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Nystatin 500,000 Unit oral tablets in a 90-count configuration. This contract utilizes a firm fixed price structure with no set-aside designation, indicating competitive award. The delivery order is scheduled for ultimate completion by July 9, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child delivery order under a larger contract vehicle supporting federal pharmaceutical procurement requirements. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to support military healthcare systems and federal medical procurement needs. The company's contract awards with the DLA demonstrate its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains through competitive procurement processes, serving customers including the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/8/25 |